Bioconjugation And Protein Modification
GBI offers a unique and unrivalled expertise in the research, development, validation and multi-gram manufacture of antibody drug conjugates, and other protein bioconjugates. GBI has many years of experience and multiple patents pending in protein modifications through chemical bioconjugation of cancer drugs, protein toxins, bifunctional ligands and metal chelates (for radio-isotope labeling), antibodies and other biological molecules onto monoclonal antibodies and recombinant proteins..
To learn more about our collaboration on radiolabeled antibody conjugates with the Albert Einstein College of Medicine, click here
Whether the conjugate is a drug toxin (small molecule cancer drugs, plant protein toxins), chelating agents for radio isotopes labeling (diagnostics and therapeutics), adjuvants such as Aluminum Hydroxide-Antibody drug conjugate, or other antibodies, GBI has the ability to develop and perform them at GMP compliant manufacturing scales for clinical applications.